The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Integrating Imaging and multiregion biopsy sampling in VHL related ccRCC
Timeframe: From month 3 to month 20
Determine immune and stromal heterogeneity in VHL-ccRCC
Timeframe: DNAseq and bulk RNAseq will be carried out from month 7 until month 20. Multiplex immunohistochemistry (IHC) in multiregional biopsies and standard IHC on the whole tumors will be performed the last 12 months of the study.
Generation and characterization of VHL-ccRCC patient-derived organoids
Timeframe: From month 3 until the end of the project.